BURLINGAME, Calif. and NEW YORK, June 21, 2018/ PRNewswire/ Ablexis LLC, and Deerfield Management announce today the acquisition of Ablexis by Deerfield Management. This acquisition creates a long-term partnership that will enable Ablexis to expand industry access to its AlivaMab Mouse technology, the company's innovative, next-generation transge
AdoRx Therapeutics, a UK based drug discovery company focused on the identification of new cancer therapeutics, today announced that it has closed an initial $10 million investment round financed by Epidarex Capital and CRT Pioneer Fund. AdoRx was founded in 2017 by leading healthcare investor Epidarex Capital and has assembled a group of highly.
Agios Pharmaceuticals, Inc. AGIO, announced the initiation of the phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with Pyruvate kinase deficiency who do not receive regular blood transfusions. The ACTIVATE study will enroll about 80 adult patients with PK deficiency who do not receive regular
CAMBRIDGE- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R enzyme. ACTIVATE is a randomized, placebo-controlled trial that
AIVITA Biomedical, a biotech company specializing in innovative stem cell applications, announced today the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase II clinical trial investigating the Company`s ROOT OF CANCER technology in patients with glioblastoma multiforme. This will be the third...
Alexion Pharmaceuticals said that it has submitted a biologics license application to the US Food and Drug Administration, seeking approval for its C5 complement inhibitor ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Alexion executive vice president and research& development head John Orloff said: This first...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in m
Amgens Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy. The company said the European Commission granted the marketing authorisation based on overall survival data from the phase 3 TOWER study, in adults with Philadelphia.
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today announced it received clearance from the Food and Drug Administration to initiate the first Phase 1 clinical trial of its immuno-oncology drug candidate AMXT 1501, a small molecule polyamine uptake inhibitor, and the approve
Its turned out to be a challenging 2018 for Anika Therapeutics new CEO Joseph Darlingand a failed phase 3 trial for lead pipeline drug Cingal wont make his job any easier. While Anika has a positive pivotal trial comparing Cingal with placebo already in hand, the latest miss means it will have to start negotiating with the FDA to see whether combin
Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced today that it will present at the 2018 Atlantic Venture Forum Technology Showcase. The event takes place June 28-29, 2018 in Halifax, Canada. Presentation details are as follows: Date: Thursday, June 28, 2018 Time: 2 p.m. Atlantic time Sessio
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced interim data from the first cohort of the Phase 2 proof-of-concept clinical trial of efgartigimod in pemphigus vulgaris patients. "There is a clear unmet ne
BOULDER- Array BioPharma Inc. announced that it will present updated safety and efficacy results, including overall survival data, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF-mutan
PASADENA- Arrowhead Pharmaceuticals Inc. today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
-Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. We are now proceeding to the final stages of this stu
BRIDGEWATER- Bausch+ Lomb, a leading global eye health company, today announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the enVista toric MX60T, the company's first hydrophobic acrylic intraocular lens for astigmatism correction. 'Building on the proven features and benefits of the enVista family of I
BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its financial results for the quarter ended March 31, 2018, and provided an update on the Company s operations.. During the past few months, we have continued to execute on our strategy to esta
Tel Aviv- BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that new data presented at the 23rd Annual Congress of the European Hematology Association, held in Stockholm, Sweden, shows that BL-8040, combined with high dose cytarabine, significantly enhanced overall survival in...
Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced it has dosed the first patient in the VOYAGER Phase 3 clinical trial, which is evaluating the safety and efficacy of avapritinib compared to regorafenib in patients with advanced...
Medical dermatology company Botanix Pharmaceuticals has raised A $8 million through an oversubscribed placement to professional, institutional and sophisticated investors across Australia and Asia. The phase 2 trial is expected to cost around A $6 million and if successful, would progress its cannabidiol-based BTX 1204 transdermal gel that aims to.
Caris Life Sciences , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced new data supporting the use of its proprietary ADAPT Biotargeting System? to drive clinical trial success. These results were presented at the European Society for Medical Oncology World Congress on Gastroint
CAMBRIDGE- Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that it will present data from the MoveDMD trial of edasalonexent at the New Directions in Biology and Disease of Skeletal Muscle Conference, the 2018 Parent Project Muscular Dystrophy Annual Connect Conference and the 15th International Congress
SOUTH SAN FRANCISCO- Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today provided an update on the ongoing Phase 1/ 2 trial investigating its next generation Factor IX candidate CB 2679 d/ISU304 for the treatment of severe hemophilia B.
The test is CE marked and in use across Europe, and available in laboratories across Australia and New Zealand. Clinical trials are underway in the U.S. in preparation for de novo clearance for the test with the U.S. Food and Drug Administration. Senior study author Associate Professor Catriona Bradshaw has worked on M. genitalium for 15 years.
"Clinical Laboratory Services" Clinical Laboratory Services- Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023. Global Clinical Laboratory Services market is estimated at $205.56 billion in 2016 and is expected to reach $333.45 billion by 2023 growing at a CAGR of 7.1% from 2016 to 2023. In North America, U.S. reg